Health Technology · Pharmaceuticals: Major · NSE: BETA · data 2026-10-09

Beta Drugs Ltd.

Health check: Strong (6.5/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹1,950.2

Market cap

₹2,104 cr

P/E

44.1

P/B

—

ROE

18.8%

ROCE

16.6%

Debt / equity

0.62

Dividend yield

0.00%

1-year return

9.6%

52-week high

₹2,807.9

52-week low

₹990.1

Operating margin

16.0%

Growth

Revenue (last 12 months)	₹410 cr
Net profit (last 12 months)	₹46 cr
Sales growth, 3 years (yearly)	19.2%
Profit growth, 3 years (yearly)	10.5%

Chart patterns

Double top — breakdown (key level ₹1,980)

Similar companies

Sai Parenterals Limited (SAIPARENT) · Sakar Healthcare Ltd (SAKAR) · Indoco Remedies Limited (INDOCO) · Panacea Biotec Limited (PANACEABIO) · Windlas Biotech Ltd. (WINDLAS)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open BETA in NSE Scanner →